Plain-English translation of NCT06557460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called the CPCB-RPE1 implant, which is a tiny patch designed to be placed under the retina to help restore vision in people with advanced dry macular degeneration (a condition where the center of the eye gradually loses function). Researchers want to see if this implant is safe and whether it can improve or stabilize vision in patients whose condition has significantly affected their sight. About two-thirds of participants will receive the real implant, while one-third will receive a sham procedure so researchers can fairly compare results.
Currently, there are very few treatment options for advanced dry macular degeneration with geographic atrophy, and many people continue to lose vision despite available therapies. This trial is exploring whether the new implant can offer hope to patients with this advanced form of the disease by potentially replacing damaged tissue in the eye.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will have eye surgery to either receive the CPCB-RPE1 implant or a sham procedure (you will not know which). The surgery involves removing the gel inside your eye and placing the implant under the retina. After surgery, you will need to maintain specific head positioning and use prescribed eye drops. You will return for multiple follow-up visits where your vision, eye health, and any side effects will be carefully monitored over the study period.
AI-generated summary from trial data · Oct 5, 2026 · Not medical advice
United States